Novel angiotensin II inhibitors in cardiovascular medicine

Bibliography

• BRUNNER HR, KIRSMAN DJ, SEALEY JE, LARAGH JH: Hypertension of renal origin: evidence for two different mechanisms. Science (1971) 174:1344–1346.
   PubMed Web of Science ®Google Scholar
• GAVRAS H, BRUNNER HR, VAUGHAN ED, JR LARAGH JH: Angiotensin-sodium interaction in blood pressure maintenance of renal hypertensive and normotensive rats. Science (1973) 180:1369–1372.
   PubMed Web of Science ®Google Scholar
• BRUNNER HR, GAVRAS H, LARAGH JH, KEENAN R: Angiotensin-II blockade in man by Sar1-A1a8-angiotensin II for understanding and treatment of high blood pressure. Lancet (1973) 2:1045–1048.
   PubMed Web of Science ®Google Scholar
• BRUNNER HR, GAVRAS H, LARAGH JH, KEENAN R: Angiotensin-II blockade in man by Sar1-A1a8-angiotensin II for understanding and treatment of high blood pressure. Lancet (1973) 2:1045–1048.
   PubMed Web of Science ®Google Scholar
• GAVRAS H, FLESSAS A, RYAN TJ etal.: Angiotensin II inhibition: Treatment of congestive cardiac failure in a high-renin hypertension. JAMA (1977) 238:880–892.
   Google Scholar
• FERGUSON RK, TURINI GA, BRUNNER HR et al..: A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet (1977) 1:775–778.
   PubMed Web of Science ®Google Scholar
• BRUNNER HR, GAVRAS H, WAEBER B etal..: Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann. Int. Med. (1979) 90:19–23.
   Google Scholar
• TURINI GA, BRUNNER HR, FERGUSON RK et al.: Congestive heart failure in normotensive man: haemodynamics, renin and angiotensin II blockade. Br Heart J. (1978) 40:1134–1142.
   PubMedGoogle Scholar
• NEAL B. MACMAHON S, CHAPMAN N: Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet (2000) 356(9246):1955–1964.
   Google Scholar
• •A large meta-analysis suggesting that ACE inhibitors are as effective as diuretics and [3-blockers in reducing cardiovascular morbidity and mortality.
   Google Scholar
• THE HEART OUTCOMES
   Google Scholar
• •• PREVENTION EVALUATION STUDY INVESTIGATORS: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl. j Med. (2000) 342:145–153.
   Google Scholar
• •First trial demonstrating the benefits of blocking the renin-angiotensin system in cardiovascular risk patients.
   Google Scholar
• THE HEART OUTCOMES PREVENTION EVALUATION (HOPE) STUDY INVESTIGATORS: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet (2000) 355:253–259.
   PubMed Web of Science ®Google Scholar
• BELL DS: Hypertension and antihypertensive therapy as risk factors for Type 2 diabetes mellitus. N Engl.j Med. (2000) 343(8):580–585.
   PubMed Web of Science ®Google Scholar
• THE CONSENSUS TRIAL STUDY GROUP: Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl. Med. (1987) 316:1429–1435.
   PubMed Web of Science ®Google Scholar
• PFEFFER MA, BRAUNWALD E, MOYE LA eta].: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl. I Med. (1992) 327:669–677.
   Google Scholar
• LEWIS EJ, HUNSICKER LG, BAIN RP etal.: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. (1993) 329:1456–1462.
   Google Scholar
• MACKENZIE HS, BRENNER BM: Current strategies for retarding the progression of renal disease. Am. I Kidney Dis. (1998) 31:161–170.
   PubMed Web of Science ®Google Scholar
• THE PROGRESS COLLABORATIVE GROUP: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet (2001) 358:1033–1041.
   PubMed Web of Science ®Google Scholar
• CORVOL P, CHAUVEAU D, JEUNEMAITRE X, MENARD J: Human renin inhibitor peptides. Hypertension (1990) 16:1–11.
   PubMed Web of Science ®Google Scholar
• •A complete review on renin inhibitors.
   Google Scholar
• NUSSBERGER J, WUERZNER G, JENSEN C, BRUNNER HR: The orally active renin inhibitor SPP100 blocks the renin angiotensin system in humans equally well as enalapril. Am. I Hypertens. (2001) 14 (4):17A.
   Google Scholar
• BURNIER M: Angiotensin II Type 1 receptor blockers. Circulation (2001) 103:904–912.
   PubMed Web of Science ®Google Scholar
• •The latest review on ATi receptor antagonists.
   Google Scholar
• MIZUNO M, SADA T, IKEDA M etal.: Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur. I Pharmacol (1995) 285(2):181–188.
   Google Scholar
• PUCHLER K, NUSSBERGER J, LAEIS P,WITTE PU, BRUNNER HR: Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients. Hyperteris. (1997) 15(12 II):1809–1812.
   Google Scholar
• PITT B, POOLE-WILSON PA, SEGAL R eta].: Randomised trial of losartan versus captopril on mortality in patients with symptomatic heart failure: the losartan heart failure survival study - ELITE II. Lancet (2000) 355:1582–1587.
   Google Scholar
• COHN J, TOGNONI G, GLAZER R, SPORMAN D, HESTER A: Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. I Card. Fail. (1999) 5:155–160.
   PubMed Web of Science ®Google Scholar
• BRENNER B, COOPER ME, DE ZEEUW D et al.: Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl. Med. (2001) 345:861–869.
   Google Scholar
• ••First demonstration of the efficacy oflosartan in reducing the progression of nephropathy in patients with Type 2 diabetes.
   Google Scholar
• LEWIS E, HUNSICKER LG, CLARKE WR et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. (2001) 345:851–860.
   PubMed Web of Science ®Google Scholar
• ••First demonstrations that irbesartan issuperior to placebo and amlodipine in retarding the progression of renal disease in Type 2 diabetes.
   Google Scholar
• PARVING HH, LEHNERT H, BROCHNER-MORETENSEN J, GOMIS R, ANDERSEN S, ARNER: The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N Engl. J Med. (2001) 345:870–878.
   PubMed Web of Science ®Google Scholar
• •First evidence in a large group of patients, that an ATi receptor blocker retards the progression from microalbuminuria to overt proteinuria.
   Google Scholar
• SEYMOUR AA, ASAAD MM, LANOCE VM et al: Systemic haemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dog with pacing-induced heart failure. I Pharmacol Exp. Ther (1993) 266:872–883.
   Google Scholar
• PHAM I, GONZALEZ W, EL AMRAANI Al et al.: Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. I Pharmacol Exp. Ther. (1993) 265:1339–1347.
   Google Scholar
• FAVRAT B, BURNIER M, NUSSBERGER J et al: Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. I Hyperteris. (1995) 13:797–804.
   PubMed Web of Science ®Google Scholar
• FINK CA: Recent advances in the development of dual angiotensin-converting enzyme and neutral endopeptidase inhibitors. Exp. Opiri. Ther. Patents (1996) 6(11):1147–1164.
   Web of Science ®Google Scholar
• •A comprehensive review on NEP/ACE inhibitors in development.
   Google Scholar
• LAURENT S, BOUTOURYIE P, AZIZI M et al: Antihypertensive effects of fasidopril, a dual inhibitor of neprilysin and angiotensin-converting enzyme in rats and humans. Hypertension (2000) 35:1148–1153.
   PubMed Web of Science ®Google Scholar
• TRIPPODO NC, ROBL JA, ASSAAD MM eta].: Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS 182,657 in experimental hypertension and heart failure. I Pharmacol Exp. Ther. (1995) 275:745–752.
   Google Scholar
• TRIPPODO NC, ROBL JA, ASSAAD MM et al: Effects of omapatrilat in low, normal and high renin experimental hypertension. Am. J Hyperteris. (1998) 11:363–372.
   PubMed Web of Science ®Google Scholar
• FRENCH JF, ANDERSON BA, DOWNS TR, DAGE RC: Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rat with hypertension. Cardiovasc. Pharmacol (1995) 26:107–113.
   PubMed Web of Science ®Google Scholar
• BURRELL LM, DROOGH J, MAN INT VELD 0, ROCKELL MD, FARINA NK, JOHNSTON CI: Antihypertensive and antihypertrophic effects of omapatrilat in SHR. Am. J. Hyperteris. (2000) 13(10):1110–1116.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-VERA W, FOURNIE- ZALUSKI MC, PHAM I et al: Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats. j Pharmacol Exp. Ther. (1995) 272:343–351.
   PubMed Web of Science ®Google Scholar
• ROBL JA, SUN CQ, STEVENSN J et al.: Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin converting enzyme and neutral endopeptidase. j Med. Chem. (1997) 40:1570–1577.
   PubMed Web of Science ®Google Scholar
• TRIPPODO NC, FOX M, MONTICELLO TM, PANCHAL BC, ASAAD MM: Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. j Cardiovasc. Pharmacol (1999) 34(6):782–790.
   PubMed Web of Science ®Google Scholar
• THOMAS CV, MCDANIEL GM, HOLGREFE HH et al.: Chronic dual inhibition of angiotensin converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs. I Cardiovasc. Pharmacol (1998) 32:902–912.
   PubMed Web of Science ®Google Scholar
• KULLO IJ, MILLER VM, LAWSON GM, BURNETT JC: Dual inhibition of neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE) suppresses atherogenesis and improves endothelial function in hypercholesterolaemic rabbits. Am. Coll. Cardiol (1996) 272(Suppl. A):164A.
   Google Scholar
• WALLIS EJ, RAMSAY LE, HETTIARACHCHI J: Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension. Clin. Pharmacol. Ther. (1998) 64:439–449.
   PubMed Web of Science ®Google Scholar
• NORTON G, WOODIWISS A, HARTFORD C etal.: Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am. I Hypertens. (1999) 12:563–571.
   Google Scholar
• ROUSSO P, BUCLIN T, NUSSBERGER J, BRUNNER-FERBER F, BRUNNER HR, BIOLLAZ J: Bioavailability of repeated oral administration of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteers. Eur. j Chit Pharmacol (2000) 55(10):749–754.
   PubMed Web of Science ®Google Scholar
• ROUSSO P, BUCLIN T, NUSSBERGER J et al.: Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers. Hypertens. (1999) 17(3):427–437.
   Web of Science ®Google Scholar
• RUDDY M, GUTHRIE R, PAPADEMETRIOU V etal.: The safety and 24-hour antihypertensive efficacy of the vasopeptidase inhibitor omapatrilat: a pilot study. Am. ..J. Hypertens. (1999) 12\(Pt 2):125A.
   Google Scholar
• ASMAR R, FREDEB OHM W, SENFTLEBER I et al.: Omapatrilat compared with lisinopril in treatment of hypertension as assessed by ambulatory blood pressure monitoring. Am. I Hypertens. (2000) 13:143A.
   Google Scholar
• RUILOPE LM, PLANTINI P, GROSSMAN E etal.: Randomised, double-blind comparison of omapatrilat with amlodipine in mild to moderate hypertension. Am. j Hypertens. (2000) 13\(Pt 2):134A.
   Google Scholar
• MCCLEAN DR, IKRAM H, GARLICK AH, CROZIER IG: Effects of omapatrilat on systemic arterial function in patients with chronic heart failure. Am. j Cardiol (2001) 87(5):565–569.
   PubMed Web of Science ®Google Scholar
• TROUGHTON RW, RADEMAKER MT, POWELL JD et al.: Beneficial renal and haemodynamic effects of omapatrilat in mild and severe heart failure. Hypertension (Online) (2000) 36(4):523–530.
   PubMed Web of Science ®Google Scholar
• MCCLEAN DR, IKRAM H, GARLICK AH, RICHARDS AM, NICHOLLS MG, CROZIER IG: The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. _J. Am. Col. Cardiol (2000) 36(2):479–486.
   PubMed Web of Science ®Google Scholar
• ROULEAU JL. PFEFFER MA. STEWART DJ et al.: Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet (2000) 356 (9230) :615–620.
   Google Scholar
• •The first clinical trial suggesting that omapatrilat is more effective than an ACE inhibitor in heart failure patients.
   Google Scholar
• BLAIS C JR FORTIN D, ROULEAU JL, MOLINARO G, ADAM A: Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts. I Pharmacol Exp. Ther. (2000) 295(2):621–626.
   PubMed Web of Science ®Google Scholar
• NUSSBERGER J, CUGNO M, AMSTUTZ C etal.: Plasma bradykinin in angio-oedema. Lancet (1998) 351:1693–1697.
   Google Scholar